Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
This pilot video slide presentation covers the development of our current standards for first line chemotherapy to treat advanced non-small cell lung cancer.
[powerpress]
These series will be called GRACEcasts (love it?), and we're in the process of developing a bunch of audio interviews with experts for an audio channel, and multiple video presentations, which are going to be about 10 minutes each, just little chapters at one time.
And you don't need to worry about getting all of the information in one viewing, because we'll plan to upload a copy of the slides and a transcript of the narration that you can download and review anytime.
Adv NSCLC First Line Chemo Slide Set
Adv NSCLC First Line Chemo Transcript
Where to next? Here's a list of some planned video GRACEcasts for the coming months:
Intro to SCLC
Limited SCLC
First Line Treatment of SCLC
Relapsed SCLC
General principles of Adjuvant Therapy for Resected NSCLC
Adjuvant Chemo for Stage I NSCLC
Management Options for Stage IIIA NSCLC
Optimal Treatment of Unresectable Locally Adv NSCLC
Angiogenesis for First Line Treatment of Adv NSCLC
EGFR-Based Therapy for Advanced NSCLC
Second Line Chemo for Adv NSCLC
Timing Therapy in Adv NSCLC: The Evolving Role of Maintenance Therapy
Rash/toxicity Management with EGFR Inhibitors
Histology Matters: Tailoring therapy by Histology for NSCLC
Molecular markers for EGFR-based Therapy
Treatment of Poor risk/elderly pts with Adv NSCLC
Combinations of Targeted Therapies
Multi-Targeted Therapies
Got ideas for more topics? We're open to suggestions. And we'd also be eternally grateful for sponsorhip of one of these key presentations, a great way to show your support for the cancer community. Just e-mail us at info@cancergrace.org.
We hope you like our transition into audio and video.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: